Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONSENSI is an oral tablet approved by the FDA in May 2018 under NDA classification. The mechanism of action, pharmacologic class, and specific indications are not disclosed in available data. The drug is currently in peak lifecycle stage, indicating it has achieved market maturity.
Peak12.1 years to LOE
Product is in peak commercial phase with no reported competitive pressure, suggesting a stable but mature market position with established field teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONSENSI currently shows zero linked job openings, indicating either a fully staffed mature brand or underdeveloped career pathway visibility. Working on this product would involve stable, peak-phase commercial execution with limited portfolio growth opportunities.
Brand ManagerField Sales Representative
Worked on CONSENSI at Purple Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.